Welcome to our dedicated page for Miromatrix Medical news (Ticker: MIRO), a resource for investors and traders seeking the latest updates and insights on Miromatrix Medical stock.
Miromatrix Medical Inc. (symbol: MIRO) is an innovative life sciences company focused on developing bioengineered organs for transplantation. The company leverages its proprietary technology to decellularize organs and tissues from both animal and human sources, creating a platform for producing fully transplantable human organs. This cutting-edge technology aims to address the critical shortage of donor organs, potentially saving and improving countless lives.
Miromatrix has garnered significant recognition for its pioneering work. The company's CEO, Dr. Jeff Ross, recently presented their advancements in kidney bioengineering at the American Transplant Congress (ATC), where they received the prestigious Best in Congress acknowledgment. Additionally, Miromatrix's Medical Director, Dr. Jack Lake, was honored with the American Society of Transplantation's 2023 Lifetime Achievement Award, the Society's highest honor, for his outstanding contributions to the field of transplantation.
The company's current focus is on the development of human livers and kidneys, utilizing its perfusion technology platform. This platform is designed to efficiently scale the bioengineering process, making it feasible to produce a larger number of transplantable organs. Miromatrix is actively involved in various research initiatives and collaborates with leading scientists such as David Lo to advance their technology further.
Financially, Miromatrix recently reported their second-quarter 2023 results, showcasing their progress and strategic direction. They continue to engage with investors and the media through scheduled presentations at significant events such as the ARM Tissue and Engineering and Therapeutics Workshop and the H.C. Wainwright Annual Global Investment Conference.
For the latest updates and detailed information on Miromatrix Medical Inc., including their recent achievements and ongoing projects, visit their official website at miromatrix.com.
Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences innovator, is presenting at the 2023 Cell & Gene Meeting on the Mediterranean in Barcelona, Spain, from April 12 to 14. CEO Jeff Ross, Ph.D., will moderate a panel on April 13 at 2:00 PM CET, discussing the challenges and opportunities in innovation. This will be followed by a company presentation at 3:30 PM CET, both of which will be live-streamed. Miromatrix focuses on bioengineering transplantable organs, addressing the human organ shortage. The event, expected to attract over 500 attendees, is pivotal for cell and gene therapy discussions including market access, regulatory frameworks, and commercialization.
The conference establishes a networking platform among industry leaders, with more than 60 presentations scheduled. For more details, visit miromatrix.com.
CareDx and Miromatrix Medical have entered an exclusive partnership to enhance the development of fully transplantable human bioengineered organs. CareDx will provide innovative testing solutions and donor-derived cell-free DNA (dd-cfDNA) testing services to assess acute allograft rejection in Miromatrix's clinical studies. This collaboration aims to address the critical organ shortage, with over 100,000 people in the U.S. awaiting transplants and 17 dying daily due to this shortage. Both companies express optimism about their joint efforts in pioneering transplant innovations.
Miromatrix Medical Inc. (NASDAQ: MIRO) reported its fourth quarter and full year 2022 financial results, emphasizing its focus on the miroliverELAP™ therapy for acute liver failure patients. The company aims to achieve FDA clearance for a Phase 1 clinical trial and has secured a collaborative agreement with Baxter International. Financially, Miromatrix ended 2022 with $25.2 million in cash, down from $52.8 million in 2021, and reported an operating loss of $30.364 million for the year. Licensing revenue increased to $953,470 in 2022 from $33,066 in 2021, reflecting collections from Reprise Biomedical. A conference call is scheduled for March 31, 2023.
Miromatrix Medical Inc. (NASDAQ: MIRO), a leader in bioengineering fully transplantable organs, will announce its fourth quarter and full year 2022 financial results on March 31, 2023, after market close. Management will conduct a conference call at 3:30 PM CT to discuss these results. Interested parties can join the call via domestic and international numbers or through a live webcast on the company's investor relations webpage. Miromatrix focuses on utilizing its proprietary perfusion technology to address the shortage of human organs, specifically developing applications for human livers and kidneys.
FAQ
What is the market cap of Miromatrix Medical (MIRO)?
What does Miromatrix Medical Inc. specialize in?
What recent recognition has Miromatrix received?
What are Miromatrix's primary focus areas?
What technology does Miromatrix use for bioengineering organs?
How is Miromatrix addressing the shortage of donor organs?
Who are some key figures in Miromatrix?
What events has Miromatrix recently participated in?
Where can I find more information about Miromatrix?
What recent financial results has Miromatrix reported?
Who can I contact for investor relations at Miromatrix?
